Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Angiotensinogen Double Nickase Plasmid (h): sc-401013-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Angiotensinogen Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Angiotensinogen Double Nickase Plasmid (h) and Angiotensinogen Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting AGT. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Angiotensinogen Antibody (H-12): sc-374511
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Angiotensinogen Double Nickase Plasmid (h) | sc-401013-NIC | 20 µg | $410.00 | |||
Angiotensinogen Double Nickase Plasmid (h2) | sc-401013-NIC-2 | 20 µg | $410.00 |
Human AGT encodes angiotensinogen, the liver-derived precursor of angiotensin peptides that drive the renin–angiotensin system (RAS). Proteolytic processing by renin and angiotensin-converting enzyme generates angiotensin II, a key effector regulating vascular tone, sodium and water homeostasis, and endocrine signaling through AT1/AT2 receptor pathways. Downstream signaling intersects with calcium mobilization, MAPK cascades, oxidative stress responses, and transcriptional programs that shape vascular remodeling and inflammatory processes. Dysregulated AGT/RAS activity is widely studied in hypertension biology, cardiovascular and renal pathophysiology, metabolic stress, and fibrosis-associated signaling in multiple tissues.
Angiotensinogen Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the AGT locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within AGT. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt AGT function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of AGT-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.